The use of recombinant factor VIII products in previously treated patients with hemophilia A: Pharmacokinetics, efficacy, safety, and inhibitor development

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 3, 2002, Pages 241-246

  Lee, Christine ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cost; Dose; Half life; Recombinant factor VIII; Recovery

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA RECOMBINATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEMOPHILIA A; HUMAN; INHIBITION KINETICS; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; COMPARATIVE STUDY; ECONOMICS; HALF LIFE TIME;

CLINICAL TRIALS; COMPARATIVE STUDY; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HEMORRHAGE; HUMAN; RECOMBINANT PROTEINS; HUMANS;

EID: 0036017370     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-32657     Document Type: Review

References (19)

1. Characterization of the human factor VIII gene
2. Molecular cloning of a cDNA encoding human antihaemophilic factor
3. Structure of human factor VIII
4. Expression of active human factor VIII from recombinant DNA clones
5. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A
6. In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency)
7. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: Conclusions of a 5-year study of home therapy
8. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII
9. Synthesis, processing and secretion of recombinant human factor VIII expressed in mammalian cells
10. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells
11. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia
12. A multicentre study of recombinant factor VIII (Recombinate™) in previously treated patients with haemophilia A
13. Novel forms of B-domain deleted recombinant factor VIII molecules. Construction and biochemical characterizaton
14. B-domain deleted human recombinant factor VIII
15. Recombinant, B-domain deleted factor VIII (r-VIII SQ): Pharmacokinetics and initial safety aspects in hemophilia A patients
16. Safety and efficacy of a second generation, B-domain deleted recombinant factor VIII (9r-VIII SQ) in previously treated patients (PTPs). A four year update
17. Twice weekly prophylactic therapy in haemophilia A
18. Dose requirements for replacement therapy in hemophilia A
19. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs